Panobinostat
Brenner Tumor
National Cancer Institute (NCI)Small moleculePhase 2Dormant
B
56/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 41/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Brenner Tumor cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Docetaxel National Cancer Institute (NCI) | Phase 3 | BB |
FILGRASTIM University of Washington | Phase 2 | B |
Sargramostim University of Washington | Phase 2 | B |
FLUTICASONE University of Washington | Phase 2 | B |
Metformin University of Chicago | Phase 2 | B |
Belinostat National Cancer Institute (NCI) | Phase 2 | B |
Hycamtin National Cancer Institute (NCI) | Phase 1 | CC |
Same molecule, other indications
Panobinostat is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →